Analysis of three human interleukin 5 structures suggests a possible receptor binding mechanism  by Verschelde, J.-L et al.
Hypothesis
Analysis of three human interleukin 5 structures suggests a possible
receptor binding mechanism
J.-L. Verscheldea, C. Ampea, Y. Guisezb, C. Oefnerc, J. Vandekerckhovea, J. Taverniera;*
aFlanders’ Interuniversity Institute for Biotechnology, Department of Medical Protein Research, University Ghent, Faculty of Medicine,
K.L. Ledeganckstraat 35, 9000 Gent, Belgium
bRoche Research Gent, Jozef Plateaustraat 22, 9000 Gent, Belgium
cDepartment of Pharmaceutical Research, New Technologies, F. Ho¡mann-La Roche, Basel, Switzerland
Received 18 November 1997; revised version received 3 February 1998
Abstract We compared three crystal structures of human
interleukin 5 (hIL5) expressed in either E. coli (hIL5E.coli), Sf9
cells (hIL5Sf9) or Drosophila cells (hIL5Drosophila). The dimeric
hIL5 structures show subtle but significant conformational
differences which are probably a consequence of the different
crystallization conditions trapping this protein into one of two
states. We refer to these two distinct conformations as the ‘open’
and ‘tight’ state, according to the packing around the cleft
between the two subunits. We hypothesize that these two stable
conformational states reflect the structure of the free or receptor
bound hIL5.
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1. Introduction
Interleukin 5 (IL5) is a haemopoietin which induces di¡er-
entiation and activation of human eosinophils and basophils.
Both cell types have been implicated in the pathogenesis of
chronic allergic diseases such as asthma. Given its speci¢city
of action, antagonizing IL5 activity has attracted a consider-
able amount of attention for drug design (for a recent review,
see [1]). Underscoring the potential clinical use of IL5 antag-
onists was the recent observation that no bronchial hyper-
reactivity, a hallmark of asthma, was observed in allergen-
challenged IL5 knock-out mice [2].
IL5 belongs to a group of cytokines characterized by a
typical short chain four K-helical bundle structure [3]. In
this fold, the K-helices (referred to as A, B, C and D from
N- to C-terminus) adopt an up-up-down-down topology. IL5
is unique within this family since it is a dimer wherein the D-
helices are swapped between the monomeric domains [4].
Granulocyte-macrophage colony stimulating factor (GM-
CSF) [5], and also IL3 [6], fold into a very similar tertiary
structure, but both exist as monomeric proteins in solution.
This fold similarity is striking since almost no homology can
be detected at the primary structure level [6,7]. In contrast to
IL5, the biological repertoires of IL3 (previously known as
multi-CSF) and GM-CSF are much broader. However, the
activities on shared target cell types, such as eosinophils, are
very analogous. These observations can be explained by the
fact that IL5, IL3 and GM-CSF all bind to very related re-
ceptor complexes composed of a ligand-speci¢c K-chain and a
shared L-subunit, often referred to as L-common or Lc [8,9].
Consequently, the cell type-dependent expression pattern of
the K-subunits restricts their biological activity, and the
shared use of the Lc receptor component provides the basis
for the overlapping functionality.
Both receptor subunits belong to the class 1 cytokine re-
ceptor family, containing one extracellular and one cytoplas-
mic segment separated by a single membrane-spanning region.
Characteristic for this receptor family is the architecture of the
extracellular region consisting of so-called ‘cytokine receptor
modules’, sometimes combined with additional immunoglobu-
lin or ¢bronectin type III domains. The crystal structures of
several cytokines complexed with the extracellular domains of
their cognate receptors have been reported over the past few
years. For class 1 cytokine receptors, these now include
growth hormone/growth hormone receptor [10], interferon-Q/
interferon-Q receptor K-subunit [11] and erythropoietin (EPO)
peptide/erythropoietin receptor (EPOR) [12]. Typically, in
these complexes, the ligands bind to the outside of the elbow
formed by the two ¢bronectin type III domains within one
‘cytokine receptor module’. In all three cases, the complex is
formed between one ligand and two identical receptor mole-
cules giving a 1:2 stoichiometry. In contrast, we have previ-
ously shown that the interaction of the IL5 dimer with the
extracellular domain of its receptor K-subunit results in a 1:1
complex in solution [13]. This ratio is particularly intriguing
given the homodimeric structure of the IL5 molecule. The
exact stoichiometry of the IL5/IL5R complex on the cell mem-
brane is still unclear. In this paper we describe the detailed
comparison of three structures for human IL5 derived from
crystallographic data [4,14]. Based on the observed di¡eren-
ces, we propose an induced ¢t model for IL5 upon receptor
binding, which is in agreement with the above mentioned
stoichiometry.
2. The IL5 structure
Three human IL5 structures have been determined by x-ray
crystallography. Crystals have been obtained of recombinant
hIL5 either puri¢ed from E. coli inclusion bodies and subse-
quent renaturation [4,15,16] from the supernatant of baculo-
virus-infected Sf9 cells [17] or from a Drosophila cell culture
system [14]. The overall structures in these di¡erent IL5 crys-
tals are very similar and consist of two domains. Each domain
is built up from four helices in a prototype up-up-down-down
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con¢guration. However, three helices A, B and C are from
one monomer and the fourth helix DP is contributed by the
other monomer (respectively red and blue in Fig. 1A and B).
Between helices A and B and C and D are two short L-strands
forming a small antiparallel L-sheet (L1 and L2
0 in Fig. 1A).
The two monomers are kept together by two intermolecular
disulphide links and by the interaction of many hydrophobic
residues at the large interface (about 7000 Aî 2).
3. hIL5 crystal structures show an ‘open’ and ‘tight’
conformation
In a previous paper, Johanson et al. [14] compared the two
independently solved structures of hIL5E:coli and hIL5Drosophila
and noticed conformational di¡erences but these were not
further examined. We observed similar di¡erences after super-
position, in a pairwise manner, of the respective eukaryotic
hIL5 and hIL5E:coli structures. As a measure of divergence, we
calculated the root-mean-square deviations. The r.m.s. devia-
tions for the hIL5E:coli/hIL5Sf9 superposition of all CK atoms
is 1.7 Aî and of all non-hydrogen atoms is 2.3 Aî , comparable
to the 1.6 Aî and the 2.1 Aî for the hIL5E:coli/hIL5Drosophila
¢tting. The superposition of the hIL5 structures expressed in
eukaryotic cells resulted in a r.m.s. deviation of 0.67 Aî (CK
atoms only) and are considered as identical.
Unlike hIL5Sf9 which contains N-acetyl glucosamine, hu-
man interleukin 5 from Drosophila was enzymatically degly-
cosylated prior to crystallization. The only conformation dif-
ference, likely to be due to the presence of a carbohydrate
group on position 28 of hIL5Sf9 , is observed in the loop be-
tween helix A and strand L1. This suggests that glycosylation
does not alter the global structure of IL5 and correlates to the
observation that deglycosylation of hIL5 does not a¡ect bio-
logical activity [18^21].
The structural di¡erences between hIL5E:coli and
hIL5Eukaryotic are re£ected in the crystallographic data (Table
1). The three crystals belong to the same space group C2.
hIL5 from Sf9 and from Drosophila cells crystallized as an
exact crystallographic dimer, in contrast to the non-crystallo-
graphic 2-fold axis found for hIL5E:coli. The crystal of
hIL5E:coli has expanded unit cell dimensions especially in the
b and c direction (36.10 Aî compared to þ 24 Aî , and 56.42 Aî
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Fig. 1. Ribbon representation of the backbone of hIL5Sf9 , A: viewed along the 2-fold axis of symmetry and B: viewed by rotating ¢gure A by
90‡ around an axis perpendicular to the 2-fold axis in upright position. The two monomers are shown in red (monomer a) and blue (monomer
b) and are connected by two disulphide bridges shown in yellow. Each domain is built up from four helices (A, B, C from monomer a and DP
from monomer b) and two L-strands (L1 and L2P). C: Solvent surface representation of the cleft showing the two states: an ‘open’ state
(hIL5Eukaryotic, left) and a ‘tight’ state (hIL5E:coli , right). Both molecules are shown in the same orientation as in B. D: Domain movements of
hIL5. Shown are the backbone traces of the ‘open’ state (orange) and ‘tight’ state (other colors). The e¡ective rotation axes are rendered as ar-
rows in the color of the corresponding substructures. Two large segments were found: segment 1 (red, 83 residues) and segment 2 (blue, 90 res-
idues). The ‘open’ and ‘tight’ states of segment 2 are optimally ¢tted so that the e¡ect of the rotation of 11 degrees (relative error v= 1.5%)
around the e¡ective rotation axis (red arrow) is clearly observed in segment 1. A smaller rigid segment 3 (yellow, residues 7 to 13) was found
at the N-terminal part of helix A and rotates by 27 degrees (relative error v= 0.85%) around its e¡ective rotation axis (yellow arrow) in rela-
tion to segment 1.
J.-L. Verschelde et al./FEBS Letters 424 (1998) 121^126122
compared to þ 44 Aî , Table 1) and has a smaller L angle
(98.59‡ compared to þ 110‡). The unit cell changes are accom-
panied by domain movements in hIL5, allowing to di¡eren-
tiate between two states: an ‘open’ state (hIL5Eukaryotic) and a
‘tight’ state (hIL5E:coli). In the open state the cleft between the
two domains is signi¢cantly wider than in the tight state (Fig.
1C).
4. The occurrence of the two states of IL5 implies motion
Many of the conformational changes in proteins are char-
acterized as rigid body movements of domains or substruc-
tures. These entities are often connected by £exible joints
around which hinge bending movements produce di¡erent
conformational states of the same protein [22].
Flexibility of the hIL5 structure is seen as a hinge motion.
We used an adaptive selection procedure (HINGEFIND, [23])
for the search of rigid substructures (hereafter referred to as
‘segments’) of hIL5. This iterative procedure superimposes the
hIL5E:coli and hIL5Eukaryotic structures using di¡erent selections
of residues and the obtained best-¢tted residue sets are con-
sidered as segments. For hIL5, two segments 1 and 2 (respec-
tively red and blue in Fig. 1D), which roughly comprise the
two domains of hIL5 are distinguished. In addition, we iden-
ti¢ed a small rigid segment 3 at the N-terminal part of helix A
(yellow in Fig. 1D). The sequence numbers of the best-¢tted
residues making up the segments 1 and 2 and segment 3 are
shown in Table 2. The residue sets of segments 1 and 2 are not
exactly the same because of the small structural di¡erences
between both hIL5E:coli domains. About 80% of the hIL5
residues are part of these rigid substructures. The remaining
20% of the hIL5 residues are part of loops and N- and C-
termini (white in Fig. 1D).
To localize the hinges around which the segments rotate,
the HINGEFIND program superimposed the rigid sections of
hIL5Eukaryotic (‘open’ state) onto the equivalent structures of
hIL5E:coli (‘tight’ state). This resulted in a rigid body trans-
formation with rotation matrices and translation vectors. Ef-
fective rotation axes were then constructed by decomposition
of above rotations and the rotation angles were calculated.
The relative motion of the two rigid segments 1 and 2 can
be represented as a rotation of 11 degrees of both segments
around the e¡ective rotation axis (red arrow in Fig. 1D) turn-
ing the molecule from one state into the other state. This
rotation axis runs through the cleft. The hinge regions on
hIL5 near the rotation axis are located on helix C of both
monomers and coincide with the junctions between both seg-
ments (a77/a78 and b80/b81; Table 2). Also the N-terminus of
helix B is part of the hinge region (a41/a42 and a42/a43; Table
2). Probably longer stretches are needed to change conforma-
tion because only small dihedral changes are allowed in helical
structures. After examining the dihedral angle variation, £ex-
ible residues were found (domain 1: residues a42, a44, a46,
b87 and b88; domain 2: residues b46, a84, a86, a87 and a88;
Fig. 4). We want to point out that these observed additional
£exible residues may allow the relaxation required for the
relative rotation of both domains. Perhaps £exibility of a
residue such as a41 which has been shown by mutagenesis
analysis to be involved in hIL5RK binding may contribute
to an induced ¢t mechanism.
Segment 3 moves around a rotation axis (yellow in Fig. 1D)
shifted upwards into domain 1 compared to the main rotation
axis of hIL5 and rotates about 27 degrees in relation to seg-
ment 1 (junction = a13/a14; Table 2). Due to the closer pack-
ing, in contrast to the loose packing of the cleft, shear forces
are expected between segment 3 and domain 1.
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Table 2
Composition of the main rigid substructures
Segment 1 Segment 2 Segment 3
N-terminal helix A a14-a26 b10-b26 a7-a13
Loop AL1 a31 b31 ^
Sheet L1 a32-a35 b32-b35 ^
Loop L1B a36-a40 b36-b40 ^
Helix B a41, a43-a56 b41-b56, a42 ^
Loop BC ^ ^ ^
Helix C a65-a73, a75-a77, b81-b86 b65-b80, a78-a86, a74 ^
Loop CL2 b87, b88 a87, a88 ^
Sheet L2 b89-b92 a89-a92 ^
Helix D b93-b111 a93-a108 ^
Residues making up the junctions are underlined. Residues located in the hIL5 monomer a or b are labeled similarly (for further explanation see
Fig. 1A and D).
Table 1
Crystallographic data for hIL5E:coli , hIL5Drosophila and hIL5Sf9
hIL5Drosophila hIL5E:coli hIL5Sf9
Space group C2 C2 C2
a 118.30 122.10 118.80
b 24.30 36.10 24.40
c 43.80 56.42 44.50
K 90.00 90.00 90.00
M 110.00 98.59 109.20
Q 90.00 90.00 90.00
Resolution 2.6 Aî 2.4 Aî 2.5 Aî
one monomer in asymmetric unit dimer in asymmetric unit one monomer in asymmetric unit
deglycosylated not glycosylated glycosylated
The data are taken from Johanson et al. [14], Milburn et al. [4] and C. Oefner (unpublished data).
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The root-mean-square deviations of a least squares ¢t of
both states of hIL5, with the joints assumed £exible, and these
of the proposed rotational ¢t are similar (respectively 0.53 Aî
and 0.50 Aî for segment 1 and 2; respectively 0.38 Aî and 0.4 Aî
for segment 1 and 3) and thus proves that hinge bending is the
ultimate mode of motion for hIL5.
5. Many important residues for K and Lc subunit binding are
located on the moveable structural segments
To localize the binding domains on the hIL5 structure, an
almost complete alanine scan of the charged residues has been
performed [24,25]. All mutants were tested in two di¡erent
assay systems. First, a hIL5RK-speci¢c solid-phase binding
assay was performed to pinpoint the mutants a¡ecting the
hIL5RK interaction. Second, the hIL5 mutants were tested
for their biological activity in a proliferation assay. Such sig-
nalling only occurs when hIL5 engages an KLc complex.
Most residues shown to be involved in binding to the K-
receptor are clustered in a loop connecting L-strand 1 and
helix B and the ¢rst residue of this helix B (residues H38,
K39 and H41), in L-strand 2 (residues E89, R91, weaker e¡ect
for E90) and close to the C-terminal helix D (residues T109,
E110, W111 and I112) (Fig. 3). Clearly, several of these res-
idues are lying near or in the cleft between both IL5 mono-
meric domains and the position of these residues is changed
by the observed domain rotation.
Residue E13 in segment 3 does not contribute to hIL5RK
binding but is critical for interaction with the Lc receptor
chain (Fig. 2A). Mutations at a homologous position in
GM-CSF (E21) abolished interaction with the Lc chain and
charge reversal mutations (E21R, E21K) result in a mutant
with antagonistic activity [26^28]. Mutations at the corre-
sponding position in IL-3 (E22) seemed also to a¡ect the
interaction with the Lc subunit, although to a lesser extent
[28,29]. We previously showed that the hIL5 E13Q mutant
still binds to the receptor complex but cannot induce prolif-
eration of IL5-responsive TF1 cells and furthermore has an-
tagonistic properties [24]. This residue shows normal interac-
tion with the hIL5RK subunit but a reduced interaction with
hIL5RLc subunit (Van Ostade et al., manuscript in prepara-
tion). Since such a single amino acid change can profoundly
a¡ect the biological activity, the motion of helix A (as de-
scribed above) may have important consequences on the bio-
logical activity of hIL5.
6. Implications for the mechanism of IL5 receptor interaction
The ¢rst requirement for receptor triggering is the binding
of hIL5 to hIL5RK. One can hypothesize that the observed
conformational transition in hIL5 may be induced upon hIL5
K-receptor interaction. An induced ¢t mechanism can be pro-
posed that transforms the cleft from one state into another,
whereby the interacting residues lying around the cleft would
make closer interactions with the residues of the K-receptor.
Human IL5 has K-helices interweaved from both monomers.
The hIL5 monomers interpenetrate extensively, burying
þ 7000 Aî 2 of subunit interface area. As a result, conforma-
tional shifts are easily transmitted from one domain to the
other. These ¢ndings may o¡er an explanation for the 1:1
stoichiometry found for the IL5 dimer/IL5RK complex in sol-
ution. If hIL5 is considered as a rigid homodimeric structure
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Fig. 2. A: Localization of hIL5 mutations a¡ecting hIL5RK binding, represented by van der Waals radii of the side chains and colored by their
temperature factors (blue = high temperature). The mutants located on loop L1B and helix B (H38, K39 and H41) and on helix D (T109, E110,
W111 and I112) that are lying in or near the cleft have higher temperature factors. Residue 13 on K-helix A has a lower temperature factor
(red = low temperature). B: The residue pair Glu-46-Lys-83 forms salt bridges in hIL5Sf9 (blue) which are not present in hIL5E:coli (red). In
both structures and also in hIL5Drosophila, they have high temperature factors.
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then a 1:2 ratio could be expected. This study clearly shows
that hIL5 can undergo structural changes which may a¡ect
the stoichiometry of the complex. In such a model, a confor-
mational change may be induced in the hIL5 structure upon
binding of one hIL5RK, disrupting the second hIL5RK bind-
ing site (Fig. 3).
An alternative explanation follows the suggestion of Chai-
ken and coworkers [30] who proposed a physical occlusion
model to explain the 1:1 stoichiometry. They used a single-
chain interleukin 5 to obtain heterodimeric mutants. Their
results lead to a model of receptor recruitment by IL5 where-
by residues from both domains interact with the K-receptor. It
was suggested that the K-receptor could bind to IL5 in two
alternative but occlusive modes, favoring contact with either
one or the other four K-helical bundles.
It should be noted that other K-helical cytokines were crys-
tallized in a 1:2 binding ratio to their receptor hence excluding
sterical hindrance. These include the growth hormone/growth
hormone receptor and interferon-Q (IFN-Q)/interferon-Q recep-
tor complexes. In the latter case the IFN-Q homodimer is
complexed with two IFN-Q receptor K-subunits.
Dickason et al. [31] engineered an IL5 monomer with a
biological activity close to that of native IL5. This mono-5
variant supports maximal proliferation of an IL5-dependent
cell line albeit at an approximately 10-fold reduced speci¢c
activity. These results imply that most structural parameters
necessary for IL5 function are present within one domain.
However, the stoichiometry of the IL5RK complex on a cell
surface is still unclear at present. Hence, dimerization of
mono-5 on the cell surface receptor complex cannot be ex-
cluded. If this situation occurs in IL5/IL5RK complex forma-
tion, an analogous packing of two IL5 monomers in such a
complex could occur with less structural constraints. An ex-
ample for such dimerization of K-helical cytokines is the IL6
binding mode that leads to the formation of an IL6 hexameric
receptor ligand complex which contains two IL6 molecules
(reviewed in [32]).
We also want to point out that the proposed induced ¢t not
only may a¡ect the hIL5-hIL5RK interaction, but also the
binding of hIL5 with its Lc receptor. The movement of seg-
ment 3 alters the position of residue E13, a residue which is
critical for hIL5-hIL5RLc interaction. This may result in a
conformation of hIL5 optimal for Lc receptor binding. The
temperature factors of the E13 residues in both crystal struc-
tures are low, re£ecting its rigidity (Fig. 2A). The role of E13
as possible anchor residue in the hIL5-hIL5RLc is thereby
suggested.
7. Further support for an induced ¢t model
(1) Comparison of IL5 sequences of di¡erent species sup-
ports the notion that the residues near the joints are impor-
tant for the global motion. The residue Glu-47 next to the
£exible residue Glu-46 is substituted by glycine for rat, gerbil
and mouse IL5. The same substitution happens at position 88
for ovine and bovine IL5 (Fig. 4). These substitutions may
underscore the necessity for £exibility in this region.
(2) The residue pair Glu-46-Lys-83 at the back of the cleft
forms salt bridges in hIL5Sf9 which are not present in
hIL5E:coli structure. These residues have high temperature fac-
tors which means they are mobile and can redirect their side
chains more easily (Fig. 2B). Internal or external forces ex-
erted on the domains could destabilize the salt bridges and
allow the hIL5 dimer to adopt another conformation. The
hIL5Sf9 structure has these salt bridges formed at the back
of the cleft holding the cleft in the open state. The pH used
for the crystallization is about 6.5 (hIL5Sf9) which is lower
than the 8.5^9 used for the hIL5 structure determination of
E. coli. Protonation of the lysine residues could be involved in
the transition between the open and the tight state. These two
residues are conserved in the IL5 primary structures of di¡er-
ent species.
(3) The possibility that conformational changes are coupled
to the hIL5/soluble hIL5RK binding reaction is provided from
binding thermodynamic and kinetic experiments [14]. The
data suggest that binding does not ¢t to a simple A plus B
to AB binding model despite a 1:1 stoichiometry but rather ¢t
a conformational isomerization model. The total amount of
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Fig. 4. Alignment of known IL5 sequences of which only residues
lying in or near helix C are shown. The location of K-helices are in
bold, these of the L-sheets are in italic bold. The £exible residues
are highlighted. Two residue positions (Glu-47 and Glu-88) near or
in the £exible position that are substituted for glycines in other spe-
cies are indicated (*). Also shown are the joints (arrow) between the
two rigid fragments, the salt bridge between Glu-46a and Lys-83b
(dotted arrow) and the disul¢de bridge between Cys-44a and Cys-
86b (dashed arrow).
Fig. 3. A model of a 1:1 complex of IL5 with IL5RK and the con-
formational isomerization of both interacting molecules based on
the observations in this study. The receptor K-subunit binds IL5, in-
ducing a conformational change in IL5 which masks the other bind-
ing site. A second IL5RK molecule does not recognize the IL5 iso-
mer and fails to bind IL5.
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surface area buried in the binding reaction of hIL5 and its
soluble K-receptor that has been estimated is very large and
cannot be attributed to the interface between the two proteins
alone. These authors suggested that signi¢cant conformation-
al changes occur in the receptor although hIL5 isomerization
can also be included. In a recent paper [33], the formation of
both 1:1 and 2:1 complexes of the soluble extracellular do-
main of EPOR and a recombinant EPO is examined by cir-
cular dichroism. Occupation of the ¢rst binding site on EPO
resulted in a conformational change which further increased
upon occupation of the second binding site. This change could
occur in EPO, in the EPOR or in all molecules of the dimer or
trimer. Inactive mutants of EPO did not show any conforma-
tional change, in agreement with a connection between bind-
ing and conformational change.
In summary, we suggest that the observed transition of the
hIL5 molecule might be important in hIL5RK recognition and
binding. The fact that two hIL5 conformations are possible is
reminiscent of an induced ¢t mechanism, in which the hIL5
monomeric domains wrap around a binding site resulting in a
more tight receptor ¢t. Such an induced ¢t would then result
in a loss of the second K-receptor interaction explaining the
observed 1:1 stoichiometry and would also enable Lc receptor
binding. Con¢rmation of this model will await the elucidation
of the three-dimensional structure of the complex. Finally, we
want to point out that our observation suggests that the cleft
between the domains may represent an alternative target for
drug design.
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